INCB16562 is a selective JAK1/2 inhibitor with significant selectivity over JAK3, exhibiting potent inhibition of IL-6-induced STAT3 phosphorylation; it suppresses the proliferation and survival of IL-6-dependent myeloma cells and inhibits IL-6-induced growth of primary bone marrow-derived plasma cells; demonstrates anti-tumor activity by antagonizing myeloma xenograft growth in mice; and shows promise for research in multiple myeloma.